Nurix Therapeutics

99 articles about Nurix Therapeutics

• Nurix Therapeutics to Present at 3rd Annual Targeted Protein Degradation Summit

  10/6/2020

  Nurix Therapeutics, Inc., (NASDAQ: NRIX), a company developing targeted protein modulation drugs, today announced the Company will be presenting at the 3rd Targeted Protein Degradation (TPD) Summit held virtually.

• Nurix Therapeutics Announces Pricing of $209 Million Initial Public Offering

  7/23/2020

  Nurix Therapeutics, Inc. (Nurix), a company developing targeted protein modulation drugs, today announced the pricing of its initial public offering of 11,000,000 shares of its common stock at a price to the public of $19.00 per share. All of the shares are being offered by Nurix. The shares are expected to begin trading on The Nasdaq Global Market on July 24, 2020 under the symbol “NRIX.” The gross proceeds from the offering, before deducting u

• Nurix Therapeutics Announces Addition of Immuno-Oncology Clinical Experts to its Management Team

  6/16/2020

  Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, today announced the appointment of Dr. Michael T. Lotze as chief cellular therapy officer (CCO) and Dr. Robert J. Brown as vice president of clinical development.

• 

  How COVID-19 is Affecting Clinical Trials and Drug Supplies from Biotech Bay Companies

  6/5/2020

  Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
• 

  Nurix Closes $120 Million Financing to Support Protein Degradation Program

  3/12/2020

  It expects to use the funds to advance its wholly-owned development candidates into the clinic.

• Nurix Therapeutics and Sanofi Establish Strategic Collaboration to Develop Novel Targeted Protein Degradation Therapies

  1/9/2020

  Nurix will utilize its proprietary drug discovery platform, DELigase™, that integrates its DNA-encoded libraries and its unparalleled portfolio of E3 ligases to create small molecules designed to induce degradation of three specified drug targets, with an option by Sanofi to expand to a total of five targets.

• 

  Harnessing the Body’s Own Protein Waste Removal System to Drug the ‘Undruggable’

  1/7/2020

  How do you catch just one kind of fish in a sea of similar fish? That’s the question being answered by researchers at Nurix, except they aren’t catching fish – they are ‘catching’ proteins in your body.
• 

  BioSpace Movers & Shakers, Oct. 11

  10/11/2019

  Companies strengthen their leadership teams and boards of directors with these appointments.

• Gilead and Nurix Establish Strategic Collaboration to Develop Novel Therapies for Cancer and Other Diseases

  6/19/2019

  Collaboration will Leverage Nurix’s Proprietary Drug Discovery Platform to Identify Novel Agents that Induce Degradation of Specified Drug Targets

• 

  Gilead Strikes $2.48 Billion Deal with Nurix to Focus on Protein Degradation

  6/19/2019

  The focus will be on discovering drugs that use the body’s natural protein control processes.

• Nurix Appoints Robert Tjian, Ph.D. Of The Column Group To Its Board Of Directors

  12/7/2016

• Nurix Appoints Robert Tjian, Ph.D. Of The Column Group To Its Board Of Directors

  12/6/2016

• Nurix Strengthens Executive Leadership Team

  5/3/2016

• Nurix Announces New Appointments To Its Board Of Directors

  5/3/2016

• Celgene, Nurix Team Up on $150M Drug Development Deal

  9/17/2015

• Nurix Launches Collaboration With Mount Sinai Hospital’s Lunenfeld-Tanenbaum Research Institute To Expand Its Drug Discovery Program

  12/2/2014

• Nurix Names Arthur T. Sands, M.D., Ph.D., Chief Executive Officer

  9/18/2014

• San Francisco Biotech Startup Nurix Taps $25.1 Million Financing

  5/27/2014

• Two San Francisco Startups, Element Science And Nurix, Reap Cash From Third Rock Ventures' Rich Funding Round

  4/24/2014